At a glance
ClinicalIndex Comparison Record- ✓Diagnosed with atrial fibrillation (AF) anytime in baseline period or on index date
- ✓Prescribed apixaban or warfarin on or after AF diagnosis date (index date)
- ✓No prior oral anticoagulant use in the 180 days before index date
- ✓Age ≥80 years on index date
- ✕Valvular atrial fibrillation, post-operative AF, rheumatic AF, or mechanical-valvular AF
- ✕Cardiac surgery during baseline period
- ✕Joint replacement procedure during baseline period
- ✕Prosthetic heart valve during baseline period
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Effectiveness of Apixaban in Very Elderly Patients With NVAF Compared to Warfarin Using Administrative Claims Data
In Brief
An observational study evaluating Warfarin and Apixaban for Non-valvular Atrial Fibrillation. Completed, enrolled 77,814 participants across 1 site.
Detailed Summary
The objective of this study is to investigate safety and effectiveness of apixaban compared to warfarin in very elderly patients with Non-valvular atrial fibrillation (NVAF). In addition to the absolute age, effects on higher age-related risk factors on relative risk of apixaban to warfarin is also investigated through subgroup analyses.
Study Details
Timeline
Interventions
This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.